The Future Is Anti-Inflammatory: Redefining IBD Outcomes Through Targeting IL-23p19

Thursday, January 22, 2026

6:15 PM – 7:30 PM PT simulcast
7:15 PM – 8:30 PM MT
8:15 PM – 9:30 PM CT
9:15 PM – 10:30 PM ET

Features

  • Interactive case-based presentations and discussions
  • Online personalized quality-improvement poster-generation portal

The Satellite Symposia content and views expressed therein are those of the sponsor and not of the Crohn’s & Colitis Congress®.

Program Overview

The satellite symposium aims to enhance healthcare professionals’ capacity to utilize evidence regarding the long-term effectiveness of anti-IL23p19 biologics in making clinical decisions for ulcerative colitis (UC) and Crohn’s disease (CD). It will focus on the integration of objective measures, such as endoscopy, histology, and biomarkers, into the assessment of long-term efficacy. Additionally, the symposium will facilitate the analysis of the comparative value of corticosteroid-free remission, promoting its application in shared decision-making.

Learning Objectives

  • Apply evidence on the long-term efficacy of anti-IL23p19 biologics in clinical decision-making for UC and CD.
  • Integrate objective makers, including endoscopy, histology and biomarkers, into long-term efficacy.
  • Analyze the comparative value of corticosteroid-free remission and apply it to shared decision-making, ensuring that treatment goals are focused on patient-centered outcomes and targets for disease modification.

Target Audience

Designed for healthcare professionals (HCPs) involved in the care of patients with inflammatory bowel disease (IBD) such as gastroenterologists as well as GI physician assistants (PAs) and GI nurse practitioners (NPs).

Joint Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

Med Learning Group designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Nurses (ANCC) Credit Designation

Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.

AAPA Credit Designation Statement – Live

AAPA Credit Designation Statement – Live

Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ACCME Innovation Partner

ACCME Innovation Partner

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure Of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Disclaimer

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

Americans With Disabilities Act

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Release date: January 22, 2026
Expiration date:January 22, 2026
Estimated time to completion: 1.25 hours